Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 19.5 | 64 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 19.0 | 80 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 17.0 | 72 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 18.0 | 68 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 23.0 | 72 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 20.0 | 84 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 21.0 | 75 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 34.0 | 83 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 54.0 | 61 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 41.0 | 63 | |
N2759 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 43.0 | 84 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 46.0 | 67 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 79.5 | 58 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 83.0 | 56 | |
N2586 | Poly(I:C) | 2 | ug/mL | 3 | G-CSF | 88.5 | 54 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 19.0 | 61 | |
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 25.5 | 66 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 14.0 | 66 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 35.0 | 70 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 15.0 | 62 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 39.0 | 50 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 15.0 | 83 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 25.0 | 77 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 145.0 | 65 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | G-CSF | 159.0 | 58 |